TGF-β/Smad3 inhibit vascular smooth muscle cell apoptosis through an autocrine signaling mechanism involving VEGF-A

X Shi1,2, L-W Guo+,1,2, SM Seedial1,2, Y Si1, B Wang1, T Takayama1, PA Suwanabori1, S Ghosh1, D DiRienzo1, B Liu1 and KC Kent+1

We have previously shown that in the presence of elevated Smad3, transforming growth factor-β (TGF-β) transforms from an inhibitor to a stimulant of vascular smooth muscle cell (SMC) proliferation and intimal hyperplasia (IH). Here we identify a novel mechanism through which TGF-β/Smad3 also exacerbates IH by inhibiting SMC apoptosis. We found that TGF-β treatment led to inhibition of apoptosis in rat SMCs following viral expression of Smad3. Conditioned media from these cells when applied to naive SMCs recapitulated this effect, suggesting an autocrine pathway through a secreted factor. Gene array of TGF-β/Smad3-treated cells revealed enhanced expression of vascular endothelial growth factor (VEGF), a known inhibitor of endothelial cell apoptosis. We then evaluated whether VEGF is the secreted mediator responsible for TGF-β/Smad3 inhibition of SMC apoptosis. In TGF-β/Smad3-treated cells, VEGF mRNA and protein as well as VEGF secretion were increased. Moreover, recombinant VEGF-A inhibited SMC apoptosis and a VEGF-A-neutralizing antibody reversed the inhibitory effect of conditioned media on SMC apoptosis. Stimulation of SMCs with TGF-β led to the formation of a complex of Smad3 and hypoxia-inducible factor-1α (HIF-1α) that in turn activated the VEGF-A promoter and transcription. In rat carotid arteries following arterial injury, Smad3 and VEGF-A expression were upregulated. Moreover, Smad3 gene transfer further enhanced VEGF expression as well as inhibited SMC apoptosis. Finally, blocking either the VEGF receptor or Smad3 signaling in injured carotid arteries abrogated the inhibitory effect of Smad3 on vascular SMC apoptosis. Taken together, our study reveals that following angioplasty, elevation of both TGF-β and Smad3 leads to SMC secretion of VEGF-A that functions as an autocrine inhibitor of SMC apoptosis. This novel pathway provides further insights into the role of TGF-β in the development of IH.

Cell Death and Disease (2014) 5, e1317; doi:10.1038/cddis.2014.282; published online 10 July 2014

Restenosis is the leading cause of failure of vascular reconstructions. Intimal hyperplasia (IH), the primary contributor to restenosis, is a complex process through which enhanced vascular smooth muscle cell (SMC) proliferation, migration and inhibition of apoptosis lead to the development of a highly cellular plaque impinging on the vessel lumen.1–3 Vascular SMC apoptosis plays a critical role in the development of IH; it inhibits IH by reducing cell number.4–7 SMC apoptosis develops immediately following angioplasty and continues for up to 4 weeks.8,9 Proliferation and apoptosis of vascular SMCs after vascular intervention are opposing pathways.12 The effect of TGF-β and Smad3 is dependent upon cell type, cell density as well as conditions of culture.5,13,14 Classic, TGF-β is thought to be a growth inhibitor that induces cell cycle arrest as well as apoptosis15 and suppresses proliferation and migration of cultured vascular SMCs.16–18 However, TGF-β after angioplasty increases SMC proliferation in the arterial wall.19,20 We have recently discovered that in the context of elevated Smad3, TGF-β is transformed from an inhibitor to a stimulant of SMC proliferation, leading to enhancement of IH.2,21 Vascular endothelial growth factor (VEGF) is a family of heparin binding glycoproteins with potent angiogenic function. The VEGF family consists of five structurally related ligands that bind differentially to their receptors (VEGFR-1, -2 and -3).22 Among these five VEGF family members, the best

Abbreviations: TGF-β, transforming growth factor-β; AdGFP, adenovirus for expression of green fluorescent protein; AdSmad3, adenovirus for expression of Smad3; VEGF, vascular endothelial growth factor; IP, immunoprecipitation; IH, intimal hyperplasia; SMC, smooth muscle cell; HIF-1α, hypoxia-inducible factor-1α; FLT-1, fms-related tyrosine kinase; VEGFR, vascular endothelial growth factor receptor; PDGF, platelet-derived growth factor; ChIP, chromatin immunoprecipitation; TUNEL, terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling assay; ANOVA, analysis of variance; siRNA, small interfering RNA

Received 27.1.14; revised 26.5.14; accepted 28.5.14; Edited by A Stephanou
studied is VEGF-A that has potent angiogenic effects in several pathophysiological processes, such as wound healing and tumor metastasis. Traditionally, VEGF-A is considered an endothelial-specific growth factor important in vascular development and in the maintenance of endothelial integrity. However, there is also evidence suggesting that VEGF receptors (fms-related tyrosine kinase (FLT-1)) are also expressed and may have discrete functions in other cell types including SMCs.23–25

The effect of TGF-β on vascular SMC apoptosis has been explored and classically TGF-β has been found to be an inhibitor of apoptosis. However, the effect of TGF-β on apoptosis in the context of arterial injury has not been evaluated. The focus of this study was to determine the role of TGF-β and Smad3 in SMC apoptosis in vitro and in arteries following angioplasty. Our data reveal a novel pathway through which elevated TGF-β/Smad3 contributes to IH by inhibiting vascular SMC apoptosis through a mechanism involving SMC secretion of VEGF-A.

Results

TGF-β/Smad3 inhibits vascular SMC apoptosis through a secreted factor. Our group and others have shown that both TGF-β and its signaling protein Smad3 are elevated in injured arteries in both humans and animals.2,26 As SMC apoptosis plays a crucial role in IH, we investigated whether TGF-β/Smad3 also regulates IH through an effect on SMC apoptosis. Cultured vascular SMCs were infected with adenoviral vectors expressing Smad3 (AdSmad3; or green fluorescent protein (AdGFP)) followed by stimulation with TGF-β. SMC apoptosis was induced with UV light and apoptosis was analyzed by flow cytometry. We found that the SMC apoptotic index (Annexin-V+/7AAD−) decreased significantly (by ~50%) following Smad3 upregulation and treatment with TGF-β (Figure 1a), whereas TGF-β/Smad3 treatment alone (without UV light) had no effect on SMC apoptosis (Supplementary Figure S1). Inhibition of SMC apoptosis by AdSmad3/TGF-β was confirmed by additional studies using either H2O2 to induce apoptosis and enzyme-linked immunosorbent assay (ELISA) for DNA fragmentation for quantification, or TNF-α/cycloheximide to induce apoptosis and immunoblotting of cleaved caspase 3 to quantify (Supplementary Figure S2).

To differentiate whether this is a direct effect of Smad3 on SMCs or an indirect effect through an autocrine mechanism involving a secreted factor, conditioned media from vascular SMCs treated with TGF-β/Smad3 or controls were applied to naive vascular SMCs. Then, UV-induced apoptosis was assessed by flow cytometric analysis. The data reveal that conditioned media from Smad3-expressing, TGF-β-stimulated vascular SMCs significantly inhibited vascular SMC apoptosis (Figure 1b). The antiapoptotic effect of the conditioned media was similar to that observed following direct application of TGF-β/Smad3 to vascular SMCs. Taken together, these results demonstrate that a secreted factor (or
factors) is responsible for TGF-β/Smad3-induced inhibition of SMC apoptosis.

**TGF-β/Smad3 stimulate VEGF-A expression in VSMCs.** To determine the identity of the factor that mediates inhibition of SMC apoptosis, we performed a microarray analysis on cultured SMCs treated with TGF-β/Smad3 or AdGFP. We found that the expression of VEGF-A, a growth factor with antiapoptotic function, was increased by 7.7-fold after TGF-β/Smad3 stimulation. This increase was substantially higher than that of other growth factors such as platelet-derived growth factor (PDGF-BB) and fibroblast growth factor (FGF-2) that are also potentially antiapoptotic (Supplementary Table S1). The findings with these additional growth factors have since been confirmed by RT-PCR (data not shown). We then explored the VEGF-A isoforms that are expressed in SMCs and found that VEGF-164 mRNA levels increased significantly in Smad3-overexpressing SMCs in a time-dependent manner following treatment with TGF-β (Figure 2a). Moreover, after TGF-β treatment VEGF-A protein levels in cell lysates and the conditioned media also significantly increased in a time-dependent manner (Figures 2b and c).

**VEGF-A is the antiapoptotic factor in TGF-β/Smad3-treated vascular SMC-conditioned media.** To evaluate whether VEGF-A is the secreted factor that prevents SMC apoptosis, increasing concentrations of VEGF-A were directly applied to cultured vascular SMCs, and UV-induced cell apoptosis was then measured by flow cytometry. Figure 3a shows that VEGF-A treatment decreased apoptosis in a dose-dependent manner; VEGF-A at 5 ng/ml was sufficient to significantly inhibit SMC apoptosis. In contrast, either recombinant VEGF-A or VEGF-neutralizing antibody did not influence SMC proliferation (Supplementary Figure S3). Concentrations of VEGF-A were measured using ELISA in TGF-β/Smad3-treated vascular SMC-conditioned media. The average level was 3.2 ng/ml (Supplementary Figure S4). We then evaluated whether VEGF-A is required for the TGF-β/Smad3-induced antiapoptotic effect on vascular SMCs. A neutralizing antibody to VEGF-A164 was added to conditioned media taken from TGF-β/Smad3-stimulated vascular SMCs that were then applied to naive vascular SMCs. Flow cytometric analysis demonstrated that the neutralizing antibody to VEGF-A abolished the protective effect of conditioned media on vascular SMC survival (Figure 3b). Moreover, small interfering RNA (siRNA) to knockdown VEGF-A in TGF-β/Smad3-stimulated vascular SMCs reversed the inhibition of SMC apoptosis produced by conditioned media from TGF-β/Smad3-treated cells (Figure 3c). Taken together, these data demonstrate that TGF-β/Smad3-stimulated VEGF-A secretion into the conditioned media is necessary and sufficient for protection against SMC apoptosis.

VEGF-A signals by inducing phosphorylation of its cell surface receptor, FLT-1. Our data show increased phosphorylation of FLT-1 (Supplementary Figure S5) as well as altered morphology (compare with Supplementary Figure S6) of naive SMCs after treatment with the conditioned media from TGF-β/Smad3-stimulated SMCs. These results indicate that VEGF-A contained in conditioned media stimulated FLT-1.

**Smad3 interacts with HIF-1α and the resultant complex binds to the VEGF promoter.** Previous studies have shown that TGF-β regulates VEGF-A production through hypoxia-inducible factor-1α (HIF-1α) in macrophages.
however, the mechanism of TGF-β/Smad3-regulated VEGF-A expression in SMCs has not been explored. We tested the hypothesis that Smad3 and HIF-1α, both transcription factors, synergistically regulate VEGF-A gene transcription in vascular SMCs (Figure 4).

To determine whether Smad3 interacts with HIF-1α, immunoprecipitation was performed and the formation of a Smad3/HIF-1α complex was assessed by measuring immunoprecipitated Smad3 or HIF-1α through western blotting. At baseline, there was an association between Smad3 and HIF-1α; upregulation of Smad3 and stimulation with TGF-β significantly increased the interaction between these two proteins (Figure 4a). The results demonstrate that HIF-1α and Smad3 physically interact, and TGF-β stimulation enhances this interaction (Figure 4a). To confirm the Smad3/HIF-1α interaction, vascular SMCs were infected with AdSmad3 or AdGFP followed by stimulation with TGF-β or solvent, and then incubated with antibodies to Smad3 and HIF-1α.

Figure 3 VEGF-164 is the secreted factor that inhibits SMC apoptosis. (a) Effect of recombinant VEGF-164 on SMC apoptosis. Rat aortic SMCs were treated with 1, 2, 5, 10 or 20 ng/ml of VEGF for 12 h. The cells were then exposed to UV light for 5 min and apoptotic index was measured 6 h later as described in the Materials and Methods (* P < 0.05 compared with solvent control; n = 3). (b) Effect of VEGF neutralization on conditioned media-induced inhibition of SMC apoptosis. Rat aortic SMCs were infected with either AdGFP control or AdSmad3 followed by stimulation with solvent or TGF-β/IFN-β (5 ng/ml) for 48 h. Conditioned media were collected and incubated with the VEGF-neutralizing antibody (Nab) or goat IgG (10 μg/ml) for 1 h before application to naive vascular SMCs for 12 h. The cells were then exposed to UV light for 5 min and apoptotic index was measured 6 h later (* P < 0.05; n = 3). (c) Effect of VEGF siRNA on conditioned media-induced inhibition of SMC apoptosis. Rat aortic SMCs were infected with either AdGFP or AdSmad3 followed by stimulation with solvent or TGF-β/IFN-β (5 ng/ml) for 48 h in the presence of scrambled siRNA or VEGF siRNA. Conditioned media were collected and applied to naive vascular SMCs for 12 h. The cells were exposed to UV light for 5 min, fixed 6 h later and then subjected to TUNEL staining (see representative images) as described in the Materials and Methods; * P < 0.05; n = 3.

Figure 4 Smad3 interacts with HIF-1α and bind to the VEGF promoter. (a) Immunoprecipitation of the Smad3/HIF-1α complex. Rat vascular SMCs were infected with either AdGFP or AdSmad3 followed by stimulation with TGF-β/IFN-β (5 ng/ml) for 6 h. Immunoprecipitation (IP) was then performed as described in the Materials and Methods; IgG was used for control. Immunoprecipitated complexes were detected by western blotting (WB) using antibodies against HIF-1α or phospho-Smad3. Shown is a representative blot from three independent experiments. (b) Proximal ligation assay showing interaction of HIF-1α and Smad3 in SMCs. Rat vascular SMCs were infected with either AdGFP or AdSmad3 followed by treatment with solvent or TGF-β/IFN-β (5 ng/ml) respectively for 6 h. The cells were then fixed and the interaction between Smad3 and HIF-1α was detected by Proximity Ligation Assay (red punctate marked by arrows) as described in the Materials and Methods. Shown are representative images each from three independent experiments; the lower panel shows enlarged nuclei (blue, DAPI stained). Scale bar is 5 μm. (c and d) Quantification of Smad3/HIF-1α interaction in SMCs. Proximal ligation was quantified as the number of ligation-positive punctate (red, see b) per cell (c) or per nucleus (d). (* P < 0.05 compared with AdGFP control; n = 3). (e) Rat vascular SMCs were infected with either AdSmad3 or AdGFP and then treated with TGF-β/IFN-β (5 ng/ml) for 6 h. Cells were crosslinked to fix the interaction between protein and DNA. The cell lysates were then sonicated to yield small DNA fragments between 200 and 700 bp. The samples were then incubated with Smad3, HIF-1α antibodies or control IgG. DNA bound to Smad3 or HIF-1α was recognized by antibodies and precipitated by protein A/G agarose beads. The precipitated DNA was measured by quantitative PCR using primer pairs to proximal or distal region of VEGF promoter. (* P < 0.05 compared with IgG control; n = 3).
Fluorescent amplification products (red dots) within SMCs showed that Smad3 and HIF-1α indeed interacted (Figure 4b). The quantitative results show that there was a basal level of Smad3 and HIF-1α interaction before TGF-β/Smad3 treatment, and this interaction was significantly increased by the upregulation of Smad3 and treatment with TGF-β/Smad3 (Figure 4c). TGF-β/Smad3 treatment also significantly increased nuclear translocation of this Smad3–HIF-1α complex (Figure 4d). These results demonstrate that TGF-β/Smad3 treatment enhances the interaction between Smad3 and HIF-1α in SMCs. In order to explore the possibility that simultaneous increases in both Smad3 and HIF-1α synergistically enhance the expression of VEGF-A, we determined whether levels of HIF1α were increased following stimulation of SMCs with TGF-β/Smad3. RT-PCR revealed that at several time points following TGF-β/Smad3 stimulation, HIF1α expression did not change (Supplementary Figure S7).

We then performed chromatin immunoprecipitation (ChIP) studies to evaluate whether Smad3 or HIF-1α bind to VEGF-A promoter. Vascular SMCs were infected with either AdSmad3 or AdGFP and then treated with TGF-β (5 ng/ml) for 6 h. Cells were crosslinked to stabilize the interaction between protein and DNA. The cell lysates were sonicated to yield small DNA fragments between 200 and 700 bp. The samples were then incubated with anti-Smad3 or anti-HIF-1α antibodies or control IgG. Smad3 and HIF-1α bound to DNA fragments were detected by their respective antibody and precipitated by protein A/G agarose beads. The precipitated DNA was measured by quantitative PCR using primer pairs proximal or distal to VEGF-A promoter. The results (Figure 4e) indicate that Smad3 and HIF-1α specifically bind to chromatin in the proximal region of VEGF-A promoter.

**Increased VEGF-A expression accompanies Smad3 elevation after arterial balloon angioplasty.** In the foregoing *in vitro* experiments, we have established that elevated TGF-β/Smad3 inhibit SMC apoptosis through the regulation of VEGF-A that functions through an autocrine mechanism to inhibit SMC apoptosis (Figures 1–3). We further investigated whether TGF-β/Smad3 regulate IH through this mechanism using the balloon-injured carotid artery as a model. Male Sprague-Dawley rats underwent sham surgery (n = 4) or balloon angioplasty followed by infusion of 200 µl AdSmad3 (n = 4) or AdGFP (n = 4) (2.5 × 10^9 plaque-forming units (PFUs)/ml) over 20 min. Animals were killed at 3 or 7 days after surgery. VEGF-A-immunostained tissue sections revealed that VEGF-A expression was remarkably low in the uninjured artery (Figures 5a and d). However, VEGF-A expression increased in the media 3 days after vascular injury (Figure 5b), and further increased in the media and neointima 7 days after injury (Figure 5c). VEGF-A levels were further enhanced at 3 and 7 days in injured arteries treated with AdSmad3 (Figure 5, compare Figure e with b and Figure f with c and see the quantification in Figure g). To quantify levels of gene expression, injured carotid arteries were harvested and analyzed for Smad3 and VEGF-A mRNA by quantitative RT-PCR (Figures 5h and i). Our results show that both VEGF-A and Smad3 mRNA levels were elevated 3 days and 7 days after vascular injury in AdGFP-treated control arteries.
animals, and upregulation of Smad3 further increased VEGF-A expression (Figures 5h and i).

**Smad3 upregulation reduces cell apoptosis in the arterial wall after balloon injury.** To test whether Smad3 gene transfer decreases apoptosis in vivo, TUNEL staining was performed on sections adjacent to those used for VEGF staining that were prepared from carotid arteries infected with AdSmad3 or AdGFP control after angioplasty. TUNEL-positive apoptotic cells were rarely seen in uninjured artery (Figure 6a). However, apoptosis was significantly increased after carotid injury (Figures 6a and b). Similar to the in vitro results, AdSmad3-infused animals had a significant decrease in the number of TUNEL-positive cells compared with GFP controls following arterial injury (Figure 6c). To confirm these findings, we performed additional studies that show that AdSmad3 treatment increased VEGF but decreased apoptosis as indicated by reduced active (cleaved) Caspase-3 that was localized on the sections adjacent to those stained positive for VEGF (Supplementary Figure S8). Moreover, reducing Smad3 activity by perivascular application of a specific Smad3 inhibitor, SIS3, significantly increased the number of TUNEL-positive cells (Figures 6f–h). These results demonstrate that Smad3 upregulation inhibits and downregulation promotes cell apoptosis in the injured artery. To further determine whether VEGF-A is responsible for the decrease of apoptosis induced by Smad3 upregulation, an inhibitor to the VEGF-A receptor (FLT1) was applied to the perivascular tissue following AdGFP or AdSmad3 intraluminal infusion into balloon-injured arteries. Our data show that this inhibitor (Axitinib) abrogated the inhibitory effect of Smad3 overexpression on SMC apoptosis (Figures 6d and e) and also reduced IH (the intima/media area ratio, see Supplementary Figure S9).

Taken together, our results obtained from both in vitro and in vivo studies reveal that elevated TGF-β/Smad3 signaling stimulates VEGF-A production that in turn suppresses SMC apoptosis through an autocrine mechanism.

**Discussion**

We have identified a novel pathway through which TGF-β in the presence of elevated Smad3 inhibits SMC apoptosis through an autocrine signaling pathway involving VEGF-A. Moreover, our in vivo data suggest that this mechanism of TGF-β/Smad3-mediated, VEGF inhibition of apoptosis also occurs in arteries following angioplasty and may play an important role in the development of IH. Persuasive evidence
includes the following: from day 3 to 7 post angioplasty, Smad3 levels progressively increase in parallel with VEGF in SMCs of the arterial media (Figure 5). Moreover, viral expression of Smad3 in injured arteries further enhances VEGF expression and is accompanied by a decrease in the number of apoptotic cells and an increase in IH, whereas inhibiting Smad3 in injured arteries with SIS3 increased the number of apoptotic cells (Figure 6). Supporting a specific role for VEGF in the inhibition of apoptosis, treatment following angioplasty with Axitinib, a VEGF inhibitor, reversed the antiapoptotic effects of Smad3 (Figure 6). Thus, our data suggest that TGF-β and Smad3 stimulate the secretion of VEGF from vascular SMCs after angioplasty that in turn contributes to the growth of the neointima by reducing the number of apoptotic cells. While in our previous studies we have explored how TGF-β/Smad3 promote IH by stimulating SMC proliferation, the findings from our current study are novel in that we show that TGF-β/Smad3 also contributes to IH by suppressing SMC apoptosis. Our results not only produce new insights into the mechanism of angioplasty-induced IH, but they also provide a further explanation of the long-standing conundrum of why TGF-β stimulates apoptosis in vitro but is a potent stimulant of IH in vivo.

The in vitro effects of TGF-β are well known. In SMCs this cytokine suppresses proliferation as well as migration and promotes apoptosis. One would then logically predict that VEGF-A, a VEGF inhibitor, reversed the antiapoptotic effects of Smad3 (Figure 6). Thus, our data suggest that TGF-β and Smad3 stimulate the secretion of VEGF from vascular SMCs after angioplasty that in turn contributes to the growth of the neointima by reducing the number of apoptotic cells. While in our previous studies we have explored how TGF-β/Smad3 promote IH by stimulating SMC proliferation, the findings from our current study are novel in that we show that TGF-β/Smad3 also contributes to IH by suppressing SMC apoptosis. Our results not only produce new insights into the mechanism of angioplasty-induced IH, but they also provide a further explanation of the long-standing conundrum of why TGF-β stimulates apoptosis in vitro but is a potent stimulant of IH in vivo.

The in vitro effects of TGF-β are well known. In SMCs this cytokine suppresses proliferation as well as migration and promotes apoptosis. One would then logically predict that TGF-β would be a potent inhibitor of angioplasty-induced IH that is the consequence of SMC proliferation and migration and is diminished by SMC apoptosis. Many studies have demonstrated that TGF-β is upregulated in arteries following angioplasty or vascular intervention. However, this cytokine consistently stimulates rather than inhibits IH. Our group has made progress in deciphering this paradox. Our previous in vitro studies revealed that in the presence of elevated Smad3, TGF-β was transformed from an inhibitor into a stimulant of SMC proliferation. Moreover, there are compelling data revealing that levels of Smad3 are elevated in vivo consequent to vascular reconstruction or angioplasty. In rat carotid arteries following angioplasty, we have found that levels of Smad3 increase in the media by day 3 and peak in the media and neointima by day 14. In addition, we have previously shown that our findings in animals are translatable to human disease. We have observed that Smad3 in conjunction with cell proliferation is upregulated in human restenotic disease but not in primary atherosclerotic lesions. We (and others) have also demonstrated in vivo that following gene transfer of Smad3, TGF-β enhances SMC proliferation as well as IH, whereas reducing Smad3 inhibits IH.

The role of SMC apoptosis in IH is somewhat complex. In response to arterial injury, apoptosis occurs typically in two phases. As observed in a mouse model of transluminal arterial injury, apoptosis increased rapidly immediately after injury and peaked at 24 h, and then decreased but persisted through 14 days. It is believed that in the early stage after injury, apoptotic cells release growth factors and cytokines, stimulating SMC proliferation. Thus, early apoptosis after vascular injury may contribute to IH. In later stages, however, apoptosis reduces SMC numbers in the arterial wall, thereby inhibiting IH. We observed that following balloon injury of rat carotid arteries, VEGF levels markedly increased after 3 days (Figure 5), suggesting that elevation of VEGF in response to injury likely contributes to IH by suppressing later-stage apoptosis. In support of this proposition, compelling data from multiple reports reveal that the induction of apoptosis by various methods reduces IH in animal models. As apoptosis that develops following angioplasty has the potential to mitigate the development of IH, our findings then offer a new mechanism through which TGF-β might exacerbate restenosis by inhibiting apoptosis. Thus TGF-β, by both blocking SMC apoptosis and by promoting proliferation, is a potent initiator of events that lead to IH. Evidence indicates that apoptosis and proliferation, although different processes, are interrelated. We therefore evaluated whether VEGF-A produced by TGF-β/Smad3 might enhance SMC proliferation in addition to influencing apoptosis. Interestingly, neither recombinant VEGF-A nor FLT-1-neutralizing antibody affected SMC proliferation (Supplementary Figure S3), suggesting that the effect of VEGF-A is confined to inhibiting apoptosis and does not involve an effect on SMC proliferation.

The role of VEGF-A in the formation of IH remains controversial. Initial reports using plasmid-mediated gene transfer suggested that VEGF-A expression facilitated reendothelialization and inhibited IH following angioplasty. Alternatively, later studies with VEGF-A protein and gene transfer revealed that VEGF-A treatment increased IH in a rabbit carotid artery injury model, whereas inhibition of VEGF-A through the application of a soluble VEGF receptor (sFLT-1) attenuated IH. This protein has been tested in clinical trials where it was found to have no significant effect on restenosis. Adding to the uncertainty of VEGF’s role in IH, low levels of VEGF-A have been found to promote proliferation of endothelial cells, whereas it has been reported that VEGF-A can induce endothelial cell apoptosis in the presence of elevated TGF-β. These results collectively indicate that the role of VEGF-A in IH is complex. Our data provide a possible explanation for this complexity. The arterial wall contains multiple cell types and with the injury that accompanies angioplasty or vascular reconstruction, these cells are altered by multiple cytokines and growth factors. The consequence may be competing effects with regard to the development of IH. Specifically, VEGF-A is capable of promoting EC regeneration that prevents thrombosis and suppresses underlying IH. However, our data demonstrate that VEGF-A also prevents apoptosis of SMCs and promotes IH. Considering these two opposing effects of VEGF-A, it may not be surprising that the efforts to eliminate restenosis by directly targeting VEGF have thus far generated confounding results. As such, one might conceive of a strategy whereby arteries following angioplasty are treated simultaneously with VEGF as well as an inhibitor of Smad3 upregulation. This combination would preserve the beneficial effect of VEGF on ECs but abrogate its detrimental effect on SMC apoptosis. This strategy would be viable presuming that the effect of VEGF on endothelial cells is Smad3 independent. We and others have already demonstrated that Smad3 has an independent stimulatory effect on IH.

Following our discovery that TGF-β/Smad3 stimulate the secretion of VEGF-A from vascular SMCs, we further explored the pathways through which TGF-β promotes VEGF production. It is known that HIF-1α is a crucial transcription factor that regulates the expression of VEGF under hypoxic conditions. Therefore, we hypothesized that HIF-1α might play a role in the upregulation of VEGF-A in response to TGF-β/Smad3 stimulation. Our results showed that treatment with a specific HIF-1α inhibitor (HID) significantly decreased VEGF-A expression in a dose-dependent manner (Figure 6). This finding is consistent with previous studies demonstrating the role of HIF-1α in the regulation of VEGF expression. In conclusion, our study provides compelling evidence for a novel role of TGF-β/Smad3 in promoting VEGF-A expression through an HIF-1α-dependent pathway. This suggests a potential therapeutic strategy for mitigating restenosis by targeting both VEGF-A and HIF-1α in the context of angioplasty.
factor regulating VEGF-A production in the context of hypoxia. Moreover, it has been found that HIF-1α and Smad2/3 interact in cancer cell lines leading to VEGF-A production. How Smad3 regulates VEGF-A expression in SMCs has not been delineated. Our evaluations using both immunoprecipitation and proximity ligation clearly demonstrate a specific interaction between Smad3 and HIF-1α that appears first in the cytoplasm and then in the nucleus. Subsequent binding of this complex to the VEGF promoter leads to VEGF expression. Thus, we conclude that Smad3 and HIF-1α, both transcription factors, interact and synergistically stimulate VEGF-A expression in SMCs. Moreover, we found that HIF-1α expression did not change following TGF-β expression in SMCs. However, we found that HIF-1α expression did change following TGF-β3-mediated suppression of SMC apoptosis (Supplementary Figure S4), confirming that VEGF-A upregulation is because of elevation of Smad3 signaling rather than HIF-1α.

Taken together, our studies suggest a new mechanism through which TGF-β promotes the development of IH (Figure 7). Following the arterial injury that accompanies angioplasty, levels of TGF-β and Smad3 are both elevated. TGF-β then stimulates SMCs and through a mechanism that involves Smad3 and HIF-1α, VEGF-A is produced and secreted. Through an autocrine pathway, secreted VEGF-A, in turn, binds to and activates FLT-1 receptors on SMCs, thereby reducing SMC apoptosis. This mechanism provides a new perspective for understanding why TGF-β has disparate functions in vitro and in vivo. Whereas TGF-β, in the presence of basal levels of Smad3, has a proapoptotic effect on SMCs in vitro, culture, TGF-β following arterial injury, in the presence of elevated Smad3, is transformed into a factor that inhibits SMC apoptosis, promotes cell survival and therefore contributes to the development of IH.

Importantly, our previous studies show significantly more Smad3 expression in restenotic lesions compared with primary atheroma in patients, making Smad3 a relevant target in the treatment of human restenotic disease. Thus, this novel pathway of TGF-β/Smad3-mediated suppression of SMC apoptosis may inspire new strategies for future therapeutic interventions to effectively attenuate IH and prevent restenosis.

Figure 7 Schematic of TGF-β/Smad3-initiated inhibition of SMC apoptosis through a VEGF pathway. TGF-β activates the TGF-β receptor that in turn activates Smad3. Phospho-Smad3 translocates into the nucleus, and by interacting with HIF-1α upregulates the gene expression of VEGF-A. Secreted VEGF-A binds to its receptor, FLT-1, and activates the VEGF-FLT-1 pathway, thus inhibiting SMC apoptosis

Materials and Methods

Animals. The experiments involving animal use were carried out in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. The protocol (Permit Number: M02273) was approved by the Institutional Animal Care and Use Committee (IACUC) of the University of Wisconsin-Madison. All surgeries were performed under isoflurane anesthesia (through inhalating, flow rate 2 ml/min), and all efforts were made to minimize suffering. Animals were killed in a chamber gradually filled with CO2.

Reagents. Recombinant TGF-β, VEGF-A and the anti-VEGF-A-neutralizing antibody were from R&D Systems (Minneapolis, MN, USA). Dulbecco’s modified Eagle’s medium (DMEM) and cell culture reagents were from Invitrogen (Carlsbad, CA, USA). All the other reagents were from Sigma (St. Louis, MO, USA) unless otherwise specified.

Smooth muscle cell culture. Rat aortic vascular SMCs were isolated from the thoracocostal abdominal aorta of male Sprague-Dawley rats. Vascular SMCs were used at passages 5 to 7 for all experiments and were maintained in DMEM supplemented with 10% fetal bovine solution (FBS) at 37°C with 5% CO2. Cells were starved in DMEM containing 0.5% FBS for 24 h, and then treated with recombinant TGF-β (5 ng/ml) or equal volume of solvent (4 mM HCl and 1 μg/ml BSA final) for 48 h.

Construction of adenoviral vectors and infection of SMCs. AdSmad3 and AdGFP were constructed as previously described. AdGFP was used as a control. Vascular SMCs were infected with adenovirus (5 × 10^9 particles/cell) in DMEM containing 2% FBS for 4 h, and the medium was then changed to fresh DMEM containing 10% FBS.

Induction and determination of vascular SMC apoptosis in vitro. We used an established method with minor modifications to induce SMC apoptosis.36 SMCs were infected with AdGFP (control) or AdSmad3 followed by treatment with solvent or TGF-β for 24 h. For some experiments, naive SMCs were treated with conditioned media or recombinant VEGF. Then, SMCs were changed to serum-free medium for 4 h to synchronize the cells. The culture media were then changed back to DMEM with 10% serum for 2 h and exposed to UV light for 5 min. After 6 h of continued incubation, cells were harvested and resuspended in binding buffer (10 mM HEPES, pH 7.4, 140 mM NaCl and 2.5 mM CaCl2) with 20 μl of phycoerythrin (PE)-conjugated Annexin-V protein (Annexin-V-PE, 10 μg/ml) followed by 20 μl of 7-amino-actinomycin (7-AAD, 50 μg/ml). After 15 min of incubation at room temperature in the dark, 400 μl of binding buffer was added to stop the reaction. Apoptotic cells were assessed by binding of Annexin-V-PE along with 7-AAD exclusion to confirm the integrity of the cell membrane. Annexin-V-stained vascular SMCs were analyzed with a FACSCalibur (BD Biosciences, San Jose, CA, USA). Data acquisition was performed with the CellQuest software package (BD Biosciences) and analysis was performed with the FlowJo software (TreeStar Inc., Ashland, OR, USA). The specificity of Annexin-V binding to vascular SMCs was verified by a negative control in the presence of 5 mM EDTA.

Enzyme-linked immunosorbent assay (ELISA). ELISA was used to detect secreted VEGF-A in vascular SMC culture media using a VEGF ELISA kit based on the sandwich enzyme immunoassay technique (R&D Systems, Minneapolis, MN, USA). The absorbance was determined using a Flex Station 3 microplate reader (Molecular Devices, Sunnyvale, CA, USA).

Western blotting analysis. Cells were lysed in RIPA buffer containing protease inhibitors (50 mM Tris, 150 mM NaCl, 1% Nonidet P-40, 0.1% sodium dodecyl sulfate and 10 μg/ml aprotonin). Protein concentration was determined by Bio-Rad DC Protein Assay kit (Hercules, CA, USA). From each sample, 30 μg of protein was separated by 10% SDS-PAGE and transferred to nitrocellulose membranes. Protein levels were assessed by immunoblotting with the following antibodies: rabbit anti-VEGF (Santa Cruz Biotechnology, Santa Cruz, CA, USA), rabbit anti-phospho-Smad3 (Cell Signaling, Boston, MA, USA) and mouse anti-β-actin (Sigma). After incubation with appropriate primary and horseradish peroxidase-conjugated secondary antibodies, the specific protein bands on the membranes were visualized by using enhanced chemiluminescence reagents (Pierce, Davenport, IL, USA).
Immunoprecipitation. Briefly, cells were lysed in Nonidet P-40 buffer. Protein A-Sepharose beads (Santa Cruz Biotechnology) and 5 μg of primary antibody or control rabbit IgG was added to lysates and incubated at 4°C with constant rotation for 12 h. Following centrifugation, pelleted beads were washed five times with Nonidet P-40 buffer. The final pellets were resuspended in 20 μl of sample buffer and heated to 100°C for 5 min. Immunoprecipitated proteins were then separated on 10% SDS-PAGE, transferred to nitrocellulose membranes and detected by immunoblotting with the following primary antibodies: mouse anti-HIF-1α, rabbit anti-p-Smad3 and rabbit anti-Smad3 (Cell Signaling).

Proximity ligation assay to assess the interaction between Smad3 and HIF-1α. Vascular SMCs were infected with AdSmad3 or control virus (AdGFP) followed by stimulation with TGF-β (5 ng/ml) or solvent control for 6 h. The cells were fixed in 4% paraformaldehyde at room temperature for 10 min. The interaction between Smad3 and HIF-1α proximity was detected by Proximity Ligation Assay (Olink, Uppsala, Sweden).

Principles: Primary antibodies were mouse anti-HIF-1α (Novus Biologicals, Littleton, CO, USA) and rabbit anti-Smad3 (Abcam, Cambridge, MA, USA) to recognize the target antigens. Mouse and rabbit species-specific secondary antibodies with a unique short DNA strand attached bind to anti-Smad3 and anti-HIF-1α antibodies, respectively. When these two DNA probes are in close proximity, the DNA can interact through a subsequent addition of two other circle-forming DNA oligonucleotides. After enzymatic ligation, the DNA was amplified using a polymerase. The resulting high concentration of fluorescence amplification product is visualized with a fluorescence microscope.

Chromatin immunoprecipitation. Vascular SMCs were infected with either AdSmad3 or AdGFP and then treated with TGF-β (5 ng/ml) for 6 h. Cells were crosslinked with 1% formaldehyde for 15 min at RT, after which 125 mM glycine was added to quench the formaldehyde. The cells were then lysed in 500 μl lysis buffer supplemented with protease inhibitor cocktail (Roche Diagnostics, Basel, Switzerland). Nuclei were pelleted at 3000 g for 5 min at 4°C and resuspended in 400 μl of nuclear lysis buffer. The samples were sonicated to yield sheared DNA fragments between 200 and 700 bp and lysates were cleared by centrifugation. The samples were then incubated with 2.5 μg of Smad3 antibody, 2.5 μg of HIF-1α antibody or control IgG (Upstate/Millipore, Billerica, MA, USA) for 1 h at 4°C. To reduce nonspecific association, 30 μg of sonicated salmon sperm DNA and 50 μg of BSA (Promega, Madison, WI, USA) were added to each sample. Immunoprecipitation (IP) was carried out using 50 μl of 50% (v/v) Protein A/G PLUS-Agarose beads (Santa Cruz) at 4°C overnight. The immune complexes were washed sequentially with low-salt wash buffer, high-salt buffer, LiCl wash buffer and TE buffer. The DNA–protein complexes were eluted with 200 μl elution buffer (1.5% SDS in 50 mM NaHCO3). The samples were incubated at 65°C overnight to reverse formaldehyde crosslinks, and phenol–chloroform extracted and ethanol precipitated. The resultant purified DNA was dissolved in 20 μl of 10 mM Tris-HCl, pH 8.5, for further analysis.

Immunocytochemistry of vascular SMCs. Vascular SMCs were seeded at 50–60% confluence in DMEM medium in chambered slides (BD Biosciences) and incubated for 24 h. The cells were then infected with AdSmad3 or AdGFP and then treated with recombinant TGF-β (5 ng/ml) or solvent for 72 h. Conditioned media from AdGFP-treated or AdSmad3/TGF-β-treated SMCs were collected and incubated with 10 μg/ml VEGF-A-neutralizing antibody (Nab) or normal goat IgG for 1 h. The antibody-treated conditioned media were then added to naive SMCs and incubated for 30 min. Cells were fixed in 4% paraformaldehyde at room temperature for 10 min and permeabilized with 0.2% Triton X-100. Immunostaining for injured rat carotid arteries with or without Smad3 overexpression was performed as described previously.

Rat balloon injury model and in vivo gene delivery. Male Sprague-Dawley rats (~350 g) underwent balloon injury of the left common carotid artery as described previously. Briefly, after induction of anesthesia with isoflurane, a 2-French balloon catheter (Edwards Lifesciences, Irvine, CA, USA) was inserted through the left external carotid artery into the common carotid and inflated with 2 atm of pressure three times. After injury, animals received intraluminal administration of adenoviral vectors (2.5 × 107 PFUs in 200 μl of PBS over 20 min). The external carotid artery was then ligated, and flow was re-established through the common carotid and internal carotid arteries. In a group of rats, a chemical inhibitor of VEGF receptor (Axitinib, 3 mg) was dissolved in 300 μl of pluronic gel and applied periadventitially immediately after vascular injury. Rats were killed 3 or 7 days after injury. Half the artery was processed for mRNA analysis and the other half fixed in 4% paraformaldehyde overnight for cryopreservation in Optimal Cutting Temperature compound (OCT).

Immunohistochemistry. Frozen sections of carotid arteries were incubated with rabbit anti-VEGF antibody (Abcam) and detected with Alexa-546 conjugated donkey anti-rabbit antibody. Normal rabbit IgG was used as antibody control. For quantification, five sections from each animal were chosen. Six different fields were then imaged from each section at ×400. The relative fluorescence intensity from each image was measured using ImageJ (NIH, Bethesda, MA, USA). The ratio of fluorescence intensity compared with AdGFP-treated uninjured control was calculated. All ratios were then averaged to generate the mean and S.D. for that animal. The means were then averaged and the S.E.M. was calculated for each group of animals.

TUNEL assay. Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay was performed using an in situ cell death detection kit (Roche, Indianapolis, IN, USA). Frozen sections of carotid arteries were stained with the kit to assess DNA fragmentation as an indicator for cell apoptosis. For quantification, five sections from each animal were chosen. Six different fields were then imaged from each section at ×400, and the independent investigators then manually counted the number of positive as well as the total number of cells. This was a binary decision. Cells were either positive or negative. All ratios were then averaged to generate the mean and S.D. for that animal. The means were then averaged and the S.E.M. was calculated for each group of animals.

Real-time PCR analysis. Total RNA was isolated from cultured cells using Trizol reagent (Invitrogen) according to the manufacturer’s protocol. Stabilization of RNA harvested from arteries was performed directly using the RNAlater RNA Stabilization Reagent (Qiagen, Valencia, CA, USA) following the manufacturer’s instructions. RNA was isolated using RNeasy Plus Mini Kit (Qiagen). Potential contaminating genomic DNA was removed by using gDNA Eliminator columns provided in the kit. RNA (2 μg) was used for the first-strand cDNA synthesis (Applied Biosystems, Carlsbad, CA, USA). Quantitative RT-PCR was performed using the 7500 Fast Real-Time PCR System (Applied Biosystems). Each cDNA template was amplified in triplicate using SYBR Green PCR Master Mix (Applied Biosystems) with gene-specific primers.

Statistical analysis. Statistical analysis was conducted using a one-way analysis of variance (ANOVA) and values were presented as mean ± S.E.M. derived from at least three independent experiments, unless otherwise stated. If significant, the ANOVA was followed by Tukey’s multiple comparison test. A P-value of <0.05 is regarded as statistically significant.

Conflict of Interest
The authors declare no conflict of interest.

Acknowledgements. We thank Qiwei Wang, Stephanie Morgan, Shakti Goel, and Sarah R Franco for technical assistance and proofreading of the manuscript. This work was supported by a National Heart, Lung, Blood Institute R01 Grant (HL-068673, to KCK) and a T32 training Grant (Hl-110853 to KCK).

1. Suwanabol PA, Kent KC, Liu B. TGF-beta and restenosis revisited: a Smad link. J Surg Res 2011; 167: 287–297.
2. Tsai S, Hollenbeck ST, Ryer EJ, Edlin R, Yamanouchi D, Kundi R et al. Decreased type II/type I TGF-beta receptor ratio in cells derived from human atherosclerotic lesions. Cardiovasc Res 2000; 45: 570–578.

Cell Death and Disease
Supplementary Information accompanies this paper on Cell Death and Disease website (http://www.nature.com/cddis)